Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment

References

• The N-SSATS Report: trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011. Rockville, MD. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. April 23, 2013.
   Google Scholar
• Brisacier A-C, Collin C. Les traitements de substitution aux opiacés en France: données récentes Tendances n 94, OFDT, 2014:6.
   Google Scholar
• Turner L, Kruszewski SP, Alexander GC. Trends in the use of buprenorphine by office-based physicians in the United States, 2003–2013. Am J Addict 2015; 24(1):24–9.
   PubMed Web of Science ®Google Scholar
• Cornish R, Macleod J, Strang J, et al.. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341:c5475.
   Google Scholar
• Ponizovsky AM, Margolis A, Heled L, et al. Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse 2010; 45(1–2):288–313.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL, et al. Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug Alcohol Depend 2014;142:98–104.
   PubMed Web of Science ®Google Scholar
• Johanson CE, Arfken CL, di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012; 120(1–3):190–5.
   PubMed Web of Science ®Google Scholar
• Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18(5):228–45.
   PubMed Web of Science ®Google Scholar
• Launonen E, Alho H, Kotovirta E, Wallace I, Simojoki K. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. Int J Drug Policy. 2015 Sep;26(9):875–82.
   PubMed Web of Science ®Google Scholar
• Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65(2):197–204.
   PubMed Web of Science ®Google Scholar
• Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104(1–2):73–7.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Nielsen S. Benzodiazepines, methadone, and buprenorphine: interactions and clinical management. Am J Addict 2010; 19(1):59–72.
   PubMed Web of Science ®Google Scholar
• Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse 2011; 37(1):1–11.
   PubMed Web of Science ®Google Scholar
• Julians-Minou G, Bruch S, Peyre N, et al. Buprenorphine for the treatment of opioid dependence: a study on generic substitution conducted in community pharmacies. Therapie 2010; 65(3):241–7.
   PubMed Web of Science ®Google Scholar
• Nordmann S, Frauger E, Pauly V, et al. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol Drug Saf 2012; 21(2):184–90.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014; 47(1):27–34.
   PubMed Web of Science ®Google Scholar
• Bouquié R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, Dailly E, Jolliet P, Victorri-Vigneau C. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS One. 2014; Dec 4;9(12):e113991.
   Web of Science ®Google Scholar
• Birebent J, Dupouy J, Bismuth M, et al.. The “not substitutable” using: a comparative study of general practitioners and community pharmacists' views from prescription to delivery. Therapie 2014; 69(5):401–17.
   PubMed Web of Science ®Google Scholar
• Boczek C, Frauger E, Micallef J, et al. National and regional market penetration rates of generic's high dosage buprenorphine: its evolution from 2006 to 2008, using reimbursed drug database. Therapie 2012; 67(2):129–36.
   Google Scholar
• Sarradon-Eck A, Blanc MA, Faure M. Users sceptical about generic drugs: an anthropological approach. Rev Epidemiol Sante Publique 2007; 55(3):179–85.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 2014; 8(5):315–26.
   PubMed Web of Science ®Google Scholar
• El-Haïk Y, Frauger E, Tanti-Hardouin N, et al. Use of generic high dose buprenorphine (HDB): about a qualitative survey. Therapie 2014; 69(3):239–41.
   PubMed Web of Science ®Google Scholar
• Public Assessment Report. Decentralised Procedure. Buprenorphine 0.4 mg, 2 mg, and 8 mg sublingual tablets buprenorphine hydrochloride.UK/HI/1066/01-03/DC. UK licence no: PL 18909/0220-2. Applicant: Arrow Generics Limited, 2008:40.
   Google Scholar
• Guichard A, Lert F, Brodeur JM, et al. Buprenorphine substitution treatment in France: drug users' views of the doctor-user relationship. Soc Sci Med 2007; 64(12):2578–93.
   PubMed Web of Science ®Google Scholar
• Feroni I, Peretti-Watel P, Paraponaris A, et al. French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis 2005; 24(3):7–22.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association, APA. Diagnostic and Statistical Manual of Mental Disorders (DSM 5). Arlington, VA: APA, 2013.
   Google Scholar
• Moracchini C, Orleans V, Miloudi S, et al. Le réseau des CEIP. General practitioners' contribution to dependence assessment: the OPEMA programme. Therapie 2012; 67(4):397–404.
   Google Scholar
• Ruffion A, Marionneau N, Taïeb C, et al. Comparison of the response to I-PSS according to the mode of administration of the questionnaire: by the doctor or self-assessment by the patient. Prog Urol 2005; 15(6):1080–4.
   PubMed Web of Science ®Google Scholar
• Pacini M, Maremmani AG, Ceccanti M, Maremmani I. Former Heroin-Dependent Alcohol Use Disorder Patients. Prevalence, Addiction History and Clinical Features. Alcohol Alcohol. 2015 Jul;50(4):451-7
   PubMed Web of Science ®Google Scholar